Topical Drugs CDMO Market (By Product Type: Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products; By Service: Contract Development, Contract Manufacturing; By End-use: Pharmaceutical Companies, Biopharmaceutical Companies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Topical Drugs CDMO Market
5.1. COVID-19 Landscape: Topical Drugs CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Topical Drugs CDMO Market, By Product Type
8.1. Topical Drugs CDMO Market Revenue and Volume, by Product Type, 2024-2033
8.1.1 Semi-solid Formulations
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Liquid Formulations Drugs
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Solid Formulations
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Transdermal Products
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Topical Drugs CDMO Market, By Service
9.1. Topical Drugs CDMO Market Revenue and Volume, by Service, 2024-2033
9.1.1. Contract Development
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Contract Manufacturing
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Topical Drugs CDMO Market, By End-use
10.1. Topical Drugs CDMO Market Revenue and Volume, by End-use, 2024-2033
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Biopharmaceutical Companies
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Topical Drugs CDMO Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Service (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by End-use (2021-2033)
Chapter 12. Company Profiles
12.1. Lubrizol Life Science (U.S.)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cambrex Corporation (U.S.)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Contract Pharmaceuticals Limited (Canada)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bora Pharmaceutical CDMO (Taiwan)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Ascendia Pharmaceuticals (U.S.)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pierre Fabre group (France)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Piramal Pharma Solutions (India)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. DPT Laboratories LTD. (U.S.)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. MedPharm Ltd. (U.S.)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. PCI Pharma Services (U.S.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample